Jade Biosciences

Yahoo Finance • 21 days ago

Jade Biosciences, Inc. GAAP EPS of -$0.48 beats by $0.19

* Jade Biosciences, Inc. press release [https://seekingalpha.com/pr/20307339-jade-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (JBIO [https://seekingalpha.com/symbol/JBIO]): Q3 GAAP EPS of -$0.4... Full story

Yahoo Finance • 26 days ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for a... Full story

Yahoo Finance • last month

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ... Full story

Yahoo Finance • 2 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclona... Full story

Yahoo Finance • 2 months ago

Jade Biosciences offers $135 million equity through private placement

* Jade Biosciences (NASDAQ:JBIO [https://seekingalpha.com/symbol/JBIO]) has entered into a private placement resulting in gross proceeds of approximately $135 million to the Company. * The company is selling an aggregate of (i) 13,368,... Full story

Yahoo Finance • 2 months ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneou... Full story

Yahoo Finance • 2 months ago

Jade Biosciences Announces $135 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for a... Full story

Yahoo Finance • 3 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the po... Full story

Yahoo Finance • 4 months ago

Jade Biosciences Posts Wider Loss in Q2

Key Points Jade Biosciences reported a net loss per share of $0.86 (GAAP) for Q2 2025. The company missed analyst GAAP EPS estimates by $0.43, with the net loss per share widening significantly year over year. Research and development spe... Full story

Yahoo Finance • 4 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to... Full story

Yahoo Finance • 5 months ago

Jefferies initiates Jade Biosciences stock with Buy rating on IgAN treatment

Investing.com - Jefferies initiated coverage on Jade Biosciences (NASDAQ:JBIO), currently trading at $9.82 with a market cap of $317 million, with a Buy rating and a $16.00 price target on Monday. According to InvestingPro data, analysts’... Full story

Yahoo Finance • 5 months ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ... Full story

Yahoo Finance • 5 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announc... Full story

Yahoo Finance • 6 months ago

Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation

Guggenheim upgraded Jade Biosciences (NASDAQ:JBIO) from Neutral to Buy on Monday, setting a price target of $14.00 for the biotechnology company. The stock, currently trading at $6.76, has experienced a challenging week with a 12% decline.... Full story

Yahoo Finance • 6 months ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic... Full story

Yahoo Finance • 6 months ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announc... Full story